Intervention in Chronic Pediatric Patients and Their Families. (FACTORADAPT)
Type 1 Diabetes, Allergic Rhinitis, Allergic Asthma
About this trial
This is an interventional prevention trial for Type 1 Diabetes focused on measuring Caregivers, Adolescent, Anxiety, Depression, Quality of life, Intervention Study
Eligibility Criteria
Inclusion Criteria:
- Diagnosis at least 6 months.
- To have signed the informed consent.
Exclusion Criteria:
- No previous psychological diagnosis.
- Attention Deficit Hyperactivity Disorder(ADHD), epilepsy or brain tumor
- Infant cerebral palsy
- Not understanding the Spanish language
Sites / Locations
- University of ValenciaRecruiting
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Control Group
Experimental Group
Patients and caregivers who receive the treatment program, will previously constitute their own control group (waiting list control group).
Patients and caregivers who receive the treatment program, will previously constitute their own control group (waiting list control group). Thus, diagnostic measures will be obtained in all of them in an initial evaluation (T1), and after 6 months of this evaluation the treatment program will be started. In the first contact session at 6 months after T1 all subjects (patients and relatives) will be re-evaluated (T2) and after this the treatment program will be started (within an estimated time of 15 days maximum from this second pre-treatment evaluation, the estimated duration of treatment being 5 months). After the completion of the patient and family treatment sessions, a new diagnostic test pass will be performed (T3) (within an estimated maximum period of 15 days from the completion of treatment) in order to evaluate the post-treatment change. Thus, the estimated time between T2 and T3 will be equivalent to that between T1 and T2, being 6 months.